Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 23 , ISSUE S3 ( September, 2019 ) > List of Articles


Hemostatic Agents in Critically Ill Patients

Saurabh Kumar Das, Maheeja Maddi Reddy

Citation Information : Das SK, Reddy MM. Hemostatic Agents in Critically Ill Patients. Indian J Crit Care Med 2019; 23 (S3).

DOI: 10.5005/jp-journals-10071-23258

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2019; The Author(s).


PDF Share
  1. Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth. 2016 ;117(suppl 3):iii18-iii30.
  2. Zaidi A, Green L. Physiology of haemostasis, Anaesthesia and intensive care medicine 2019, [Article in press].
  3. Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol. 2011;39:273–280.
  4. Porte RJ, Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery Drugs 2002;62:2193–2211.
  5. Levy JH. Efficacy and safety of aprotinin in cardiac surgery Orthopedics 2004;27:S659–662.
  6. Samama CM. A direct antifibrinolytic agent in major orthopedic surgery. Orthopedics 2004;27:S675–680.
  7. Bitan FD. Aprotinin in spine surgery: review of the literature. Orthopedics 2004;27:S681–683.
  8. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185–194.
  9. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353–365.
  10. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high- transfusion-risk cardiac surgery. Transfusion 2006;46:327–338.
  11. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319–2331.
  12. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth. 2004;93:842–858.
  13. Choi, Ji-Young, Kang, Yun-Jeong, Jang, Hye Min, Jung, Hee-Yeon; Cho, Jang-Hee; Park, Sun-Hee, Kim, Yong-Lim, Kim, Chan-Duck. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Medicine.2015;94(52):p e2392. doi: 10.1097/MD.0000000000002392.
  14. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236–261.
  15. Franck M, Sladen RN. Drugs to prevent and reverse anticoagulation. Anesthesiol Clin North America 1999;17:799–811.
  16. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258–1267.
  17. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briët E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a metaanalysis of clinically relevant endpoints. Lancet 1999;354:1940–1947.
  18. Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemelä HM, Mäntylä SK, et al. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997;84:839–844.
  19. Ekbäck G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckström J, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000;91:1124–1130.
  20. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043–1048.
  21. Dalmau A, Sabaté A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29–34.
  22. The WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389:2105–2116.
  23. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17:1–79.
  24. Seizures after cardiac surgery. Hunter GR, Young GB J Cardiothorac Vasc Anesth. 2011;25:299–305.
  25. Leff J, Rhee A, Nair S, Lazar D, Sathyanarayana SK, Shore-Lesserson L. A randomized, double-blinded trial comparing the effectiveness of tranexamic acid and epsilon-aminocaproic acid in reducing bleeding and transfusion in cardiac surgery. Ann Card Anaesth.2019;22:265–272.
  26. Blaine KP, Press C, Lau K, Sliwa J, Rao VK, Hill. Comparative effectiveness of epsilon-aminocaproic acid and tranexamic acid on postoperativebleeding following cardiac surgery during a national medication shortage. J Clin Anesth. 2016;35:516–523.
  27. Riaz O, Aqil A, Asmar S, Vanker R, Hahnel J, Brew C, et al. Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysisstudy. J Orthop Traumatol. 2019;20:28.
  28. Mangus RS, Kinsella SB, Fridell JA, Kubal CA, Lahsaei P, Mark LO, et al. Aminocaproic Acid (amicar) as an alternative to aprotinin (trasylol) in liver transplantation. Transplant Proc. 2014;46:1393–1399.
  29. Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders Haemophilia. 2016;22:39–45.
  30. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993;7:425–430.
  31. Sheridan DP, Card RT, Pinilla JC, Harding SM, Thomson DJ, Gauthier L, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33–36.
  32. Guay J, Reinberg C, Rivard GE, Poitras B, Mathews S, David M. DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 1990;37:S14.
  33. Flordal PA, Ljungstrom KG, Ekman B, Neander G. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 1992;63:381–385.
  34. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3:138–153.
  35. Heistinger M, Stockenhuber F, Schneider B, Pabinger I, Brenner B, Wagner B, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int 1990;38:1181–1186.
  36. Shemin D, Elnour M, Amarantes B, Abuelo JG, Chazan JA. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990;89:436–440.
  37. Garay RP, Chiavaroli C, Hannaert P. Therapeutic Efficacy and Mechanism of Action of Ethamsylate, a Long-Standing Hemostatic Agent. American Journal of Therapeutics. 2006;13:236–247.
  38. Hernandez MR, Alvarez-Guerra M, Escolar G, Chiavaroli C, Hannaert P, Garay RP. The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury. Fundam Clin Pharmacol. 2004;18:423–430.
  39. Khawar H, Kelley W, Guzman N. Fresh Frozen Plasma (FFP) [Updated 2019 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from:
  40. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21:37–48.
  41. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–143.
  42. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149–154.
  43. Dutta TK, Verma SP. Rational Use of Recombinant Factor VIIa in Clinical Practice. Indian J Hematol Blood Transfus. 2014;30:85–90.
  44. Hedner U. Mechanism of Action of Factor VIIa in the Treatment of Coagulopathies. Seminars in Thrombosis and Hemostasis.2006;32;077–085.
  45. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154:516–522.
  46. Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia [published correction appears in Ann Hematol. 2018 ;97(12):2531]. Ann Hematol. 2018;97:1889–1901.
  47. von Heymann C1, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgeryincluding vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008;12:R14. doi: 10.1186/cc6788. Epub 2008 Feb 15.
  48. Stephan A Mayer, Nikolai C Brun, Kamilla Begtrup, Joseph Broderick, Stephen Davis, Michael N Diringer, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.